Open AccessEfficacy and safety of Shufeng Jiedu capsule in the treatment of COVID-19
Author(s) -
Li Ma,
Ji-Ni Song,
Yanping Song,
Li Zhao,
Hao Chen
Publication year - 2020
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000023293
Subject(s) - medicine , cochrane library , covid-19 , medline , meta analysis , protocol (science) , web of science , psychological intervention , systematic review , medical physics , intensive care medicine , alternative medicine , family medicine , disease , pathology , infectious disease (medical specialty) , nursing , outbreak , political science , law
Background: Coronavirus disease 2019 (COVID-19) epidemic is spreading worldwide. Shufeng Jiedu capsule (SFJDC) is a commonly used drug in the treatment of COVID-19. However, there is insufficient evidence for clinical efficacy and safety. Methods: Two authors will independently search the Chinese National Knowledge Infrastructure (CNKI), VIP database, Wanfang database, the Cochrane Library, EMBASE, PubMed and Web of Science, in English and Chinese. All analysis will be performed based on the Cochrane Handbook for Systematic Reviews of Interventions. Review Manager 5.3 and Stata 16.0 software will be used to analyze the eligible data. Results: This protocol will conduct a systematic review and meta-analysis of literature listed above, and reliable outcomes about the clinical efficacy and safety of SFJDC in the treatment of COVID-19 will be obtained. Conclusions: These findings will provide guidance for clinicians and patients using SFJDC for COVID-19 treatment. PROSPERO Registration Number: CRD42020185764.